| 陈震,吕雄文,徐元宏.产超广谱β-内酰胺酶大肠埃希菌的分布变迁及临床治疗研究[J].中国药事,2018,32(3):378-383 |
| 产超广谱β-内酰胺酶大肠埃希菌的分布变迁及临床治疗研究 |
| Clinical Treatment Research and Distribution Change of Extended Spectrum β-Lactamase-producing Escherichia Coli |
| 投稿时间：2017-07-17 |
| DOI：10.16153/j.1002-7777.2018.03.014 |
| 中文关键词: 产超广谱β-内酰胺酶大肠埃希菌 药物敏感性试验 细菌耐药监测 药物治疗 |
| 英文关键词: extended spectrum β-lactamase-producing escherichia coli drug sensitivity test bacterial resistance monitoring medication |
| 基金项目:安徽省自然科学基金（编号09020103002） |
|
| 摘要点击次数: 1620 |
| 全文下载次数: 870 |
| 中文摘要: |
| 目的：观察临床分离的产超广谱β-内酰胺酶大肠埃希菌（ESBL-EC）对常用抗菌药物的耐药性变迁情况及药物治疗效果。方法：监测ESBL-EC的耐药趋势并分析临床药物的治疗结果。结果：ESBL-EC对头孢他啶、左氧氟沙星、头孢哌酮舒巴坦、阿米卡星、头孢西丁、哌拉西林他唑巴坦、亚胺培南的平均耐药率分别为64.4%、62.5%、8.7%、9.6%、1.9%、0%、0%；对头孢曲松几乎全部耐药。亚胺培南西司他汀、头孢西丁、头孢哌酮舒巴坦、哌拉西林他唑巴坦对ESBL-EC感染临床治疗效果较好，依替米星治疗效果不佳。结论：临床及时监控ESBL-EC的发生率及其耐药趋势以指导临床用药至关重要。 |
| 英文摘要: |
| Objective: To observe the changes of drug resistance of extended spectrum β-lactamase-producing escherichia coli (ESBL-EC) clinically isolated to common antibiotics and the clinical treatment effect. Methods: The drug resistance trend of ESBL-EC was monitored and the clinical treatment effect was analyzed. Results: The average resistance rates of ESBL-EC to ceftazidime, levofloxacin, cefoperazone sulbactam, amikacin, cefoxitin, piperacillin tazobactam and imipenem were 64.4%, 62.5%, 8.7%, 9.6%, 1.9%, 0% and 0% respectively. The resistance rate to ceftriaxone was almost 100%. Imipenem cilastatin, cefoxitin, cefoperazone sulbactam and piperacillin tazobactam were effective in the treatment of ESBL-EC infection, and the clinical treatment effect of etimicin was not good. Conclusion: The incidence of ESBL-EC and its drug resistance trend should be clinically monitored in time so as to guide the clinical medication of drugs. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |